Literature DB >> 3002805

Characterization of the 5-HT1B recognition site in rat brain: binding studies with (-)[125I]iodocyanopindolol.

D Hoyer, G Engel, H O Kalkman.   

Abstract

(-)[125I]Iodocyanopindolol ([125I]CYP) labels rat brain membrane sites which display high affinity for several serotonergic and beta-adrenergic compounds. The binding of [125I]CYP to these serotonergic recognition sites was evaluated in the presence of 30 microM (-)isoprenaline in order to suppress binding to beta-adrenoceptors. [125I]CYP binds in rat cortex membranes rapidly, reversibly and stereoselectively to a finite number of recognition sites: Bmax = 180 fmol/mg, KD = 230 pM. Similar affinity values of [125I]CYP were obtained in membranes from rat hippocampus and striatum. Kinetic, saturation and competition experiments suggest that under these conditions [125I]CYP binds to a single serotonergic recognition site named 5-HT1B. The pharmacological profile of 5-HT1B sites is characteristic of a 5-HT1 binding site and shows the following rank order of affinity for agonists: RU 24969, (5-methoxy-3-[1,2,3,6-tetrahydropyridin-4-yl]1H-indole) greater than 5-CT, (5-carboxamidotryptamine) greater than 5-HT, (5-hydroxytryptamine, serotonin) greater than 5-OCH3-T, (5-methoxytryptamine) much greater than 2-CH3-5-HT, (2-methylserotonin) greater than 8-OH-DPAT, (8-hydroxy-2-(di-n-pro-pylamino)-tetralin). The rank order of affinity for antagonists is: (+/-)ICYP, ((+/- )-3-I-cyano-pindolol) greater than (-)21-009, (4-[3-ter-butyl-amino-2-hydroxy-propoxy]-indol-2-carbonic acid isopropyl ester) greater than (+)21-009 greater than (-)propranolol greater than metitepin greater than (-)pindolol much greater than ketanserin greater than spiroperidol greater than mesulergine. 5-HT1B recognition sites display low affinity for selective beta 1- and beta 2-adrenoceptor antagonists, e.g. atenolol, betaxolol, ICI 89-406 and ICI 118-551. The low affinity of 5-HT1B recognition sites for some 5-HT1A, 5-HT1C and 5-HT2 selective compounds (e.g. 8-OH-DPAT, mesulergine, ketanserin) suggests that 5-HT1B recognition sites are pharmacologically different from 5-HT1A, 5-HT1C and 5-HT2 recognition sites.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3002805     DOI: 10.1016/0014-2999(85)90657-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  57 in total

1.  5-HT1D binding sites in various species: similar pharmacological profile in dog, monkey, calf, guinea-pig and human brain membranes.

Authors:  A T Bruinvels; H Lery; J Nozulak; J M Palacios; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-09       Impact factor: 3.000

2.  "5-HT1R" or 5-HT1D sites? Evidence for 5-HT1D binding sites in rabbit brain.

Authors:  D Hoyer; H Lery; C Waeber; A T Bruinvels; J Nozulak; J M Palacios
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-09       Impact factor: 3.000

3.  Involvement of 5-HT1B receptors in the anticonflict effect of m-CPP in rats.

Authors:  E Chojnacka-Wójcik; A Kłodzińska
Journal:  J Neural Transm Gen Sect       Date:  1992

Review 4.  The serotonin 5-HT1D receptor: a progress review.

Authors:  C Waeber; P Schoeffter; D Hoyer; J M Palacios
Journal:  Neurochem Res       Date:  1990-06       Impact factor: 3.996

5.  The effects of aging and chronic fluoxetine treatment on circadian rhythms and suprachiasmatic nucleus expression of neuropeptide genes and 5-HT1B receptors.

Authors:  Marilyn J Duncan; James M Hester; Jason A Hopper; Kathleen M Franklin
Journal:  Eur J Neurosci       Date:  2010-05       Impact factor: 3.386

6.  Central serotonin receptors: effector systems, physiological roles and regulation.

Authors:  P J Conn; E Sanders-Bush
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 7.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

8.  The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons.

Authors:  A Dumuis; M Sebben; J Bockaert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-10       Impact factor: 3.000

9.  L-694,247: a potent 5-HT1D receptor agonist.

Authors:  M S Beer; J A Stanton; Y Bevan; A Heald; A J Reeve; L J Street; V G Matassa; R J Hargreaves; D N Middlemiss
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

10.  G protein dependent alterations in [125I]iodocyanopindolol and +/- cyanopindolol binding at 5-HT1B binding sites in rat brain membranes.

Authors:  K Ariani; M W Hamblin; G L Tan; C A Stratford; R D Ciaranello
Journal:  Neurochem Res       Date:  1989-09       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.